Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer

Abstract

Combination immunotherapy is emerging as a promising approach for the treatment of advanced prostate cancer. This research highlight discusses the combination of a PSA-directed poxviral vaccine and a monoclonal antibody blocking an important immune checkpoint molecule to treat men with metastatic castrationresistant prostate cancer. The results demonstrate feasibility and safety, as well as intriguing clinical responses to this combination therapy. © 2012 AJA, SIMM & SJTU. All rights reserved.